Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

12.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
12.2K
Allergic Drug Reactions01:27

Allergic Drug Reactions

1.4K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.4K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Allergic Reactions02:06

Allergic Reactions

32.1K
Overview
32.1K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

3.7K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cutaneous eruption by <i>Streptococcus dysgalactiae</i> in an immunocompromised patient.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same author

Dupilumab in Difficult-to-treat Chronic Spontaneous Urticaria: A Real-world Multicentre Cohort Study.

Acta dermato-venereologica·2026
Same author

ACOX1 Gain-of-Function and De Novo ROBO1 Variant in ACOX1-sEDD.

Pediatric dermatology·2026
Same author

Quick assessment of quality-of-life in itch: An exploratory validation of the 5-item pruritus life quality.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

The State of the Art in Chronic Prurigo Nodularis.

Dermatology and therapy·2026
Same author

Efficacy and Safety of Guselkumab in Real-World Evidence: A Systematic Review and Meta-Analysis.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Jan 18, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.5K

Vaccination Recommendations in Patients With Atopic Dermatitis Treated With JAK Inhibitors.

Mariano Ara-Martín1,2, Carolina Moreno3, Ricardo Ruiz-Villaverde4,5

  • 1Dermatology Unit, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.

International Journal of Dermatology
|September 10, 2025
PubMed
Summary

Janus kinase (JAK) inhibitors revolutionize atopic dermatitis treatment but require careful vaccine management. Inactivated vaccines are safe, but live attenuated vaccines are contraindicated during JAK inhibitor therapy without temporary discontinuation.

Keywords:
JAK inhibitorsatopic dermatitisrecommendationsvaccination

More Related Videos

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

23.9K
Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

502

Related Experiment Videos

Last Updated: Jan 18, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.5K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

23.9K
Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

502

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Atopic dermatitis treatment has been transformed by Janus kinase (JAK) inhibitors.
  • These immunomodulatory drugs necessitate specific precautions regarding infection risk and vaccination.

Purpose of the Study:

  • To offer dermatologists and healthcare providers practical vaccination guidelines for patients with atopic dermatitis on JAK inhibitors.
  • To address the safe administration of vaccines in adults and adolescents undergoing JAK inhibitor therapy.

Main Methods:

  • Review of current clinical guidelines and expert recommendations.
  • Analysis of vaccine safety profiles in the context of JAK inhibitor immunosuppression.

Main Results:

  • Inactivated vaccines are considered safe and recommended during Janus kinase (JAK) inhibitor treatment.
  • Live attenuated vaccines are contraindicated unless JAK inhibitor therapy is temporarily paused per clinical guidelines.

Conclusions:

  • Adherence to official vaccination guidelines, individualized for each patient, is crucial.
  • Careful patient monitoring and follow-up are essential for safety and optimal treatment outcomes in atopic dermatitis patients on JAK inhibitors.